10-K: Delcath Systems Reports Increased Revenue Following HEPZATO KIT Commercial Launch in 2024

Delcath Systems' 10-K filing reveals a significant revenue increase driven by the commercial launch of HEPZATO KIT and continued CHEMOSAT sales in Europe.

Summary

• Delcath Systems, Inc., an interventional oncology company, reported its 10-K filing for the fiscal year ended December 31, 2024.
• The company focuses on treating primary and metastatic cancers in the liver.
• A key highlight was the FDA approval and commercial launch of HEPZATO KIT in the U.S. for treating uveal melanoma with liver metastases, leading to the first commercial use in January 2024.
• In Europe, CHEMOSAT continues to be marketed for a range of liver cancers.
• The company's revenue increased significantly, from $2.1 million in 2023 to $37.2 million in 2024, primarily due to the HEPZATO KIT launch.
• The company is also pursuing clinical trials to expand the use of HEPZATO for other liver cancers, including metastatic colorectal and breast cancer.
• As of December 31, 2024, Delcath had $32.4 million in cash and cash equivalents and $20.8 million in short-term investments.
• The company believes its current resources are sufficient to fund operations for at least the next 12 months.
• The company is planning a Phase 2 trial evaluating HEPZATO in combination with standard of care for liver-dominant metastatic colorectal cancer, with patient enrollment expected to begin in the second half of 2025.
• The company is also planning to begin a study evaluating HEPZATO in combination with SOC for liver-dominant metastatic breast cancer in 2025.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While there's positive news regarding revenue growth and product approval, the company still faces challenges related to profitability, competition, and regulatory hurdles.

Positives

• FDA approval and successful commercial launch of HEPZATO KIT in the U.S.
• Significant increase in revenue driven by HEPZATO KIT and CHEMOSAT sales.
• Strong cash position with $32.4 million in cash and cash equivalents and $20.8 million in short-term investments.
• Ongoing clinical trials to expand the use of HEPZATO for other liver cancers.
• Publication of positive results from the Phase 3 FOCUS Clinical Trial.
• The company's IND application for a Phase 2 clinical trial evaluating HEPZATO in combination with standard of care for mCRC was cleared by the FDA in December 2024.

Negatives

• The company incurred net losses of approximately $26.4 million and $47.7 million for the years ended December 31, 2024 and 2023, respectively.
• The company has a substantial accumulated deficit and recurring operating losses.
• The company has limited experience as a commercial company and generating revenue from product sales.

Risks

• The company may need additional capital to maintain operations.
• The company must maintain or enter into acceptable arrangements for the supply of melphalan and other critical components of HEPZATO and CHEMOSAT.
• The company may be unsuccessful in commercializing CHEMOSAT and HEPZATO because of inadequate infrastructure or an ineffective commercialization strategy.
• The development and approval process in the United States and abroad could take many years, require substantial resources and may never lead to the approval of our product candidates by the FDA for use in the United States or by foreign regulators in their respective jurisdictions.
• The company's ability to market HEPZATO is limited to those uses that are approved.
• The company may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws.
• The company and third parties with whom it works are subject to stringent and evolving United States and foreign laws, regulations, rules, contractual obligations, industry standards, policies and other obligations related to information privacy and security.
• Changes in healthcare law and implementing regulations, including government restrictions on pricing and reimbursement, as well as healthcare policy and other healthcare payor cost-containment initiatives, may have a material adverse effect on the company.
• Intellectual property rights may not provide adequate protection, which may permit third parties to compete against the company more effectively.
• The market price of the company's common stock has been and may continue to be volatile and fluctuate significantly, which could result in substantial losses for investors.
• The loss of key personnel could adversely affect the company's business.

Future Outlook

Delcath plans to continue clinical development of HEPZATO and CHEMOSAT for a broader set of liver-dominant cancer indications, either as monotherapy or in combination with other therapies, and expects to begin a study evaluating HEPZATO in combination with SOC for liver-dominant metastatic breast cancer in 2025.

Industry Context

The healthcare industry is characterized by extensive research, rapid technological progress and significant competition from numerous healthcare companies and academic institutions. Competition in the cancer treatment industry is intense.

Comparison to Industry Standards

• The document mentions competitors such as Immunocore Holdings plc (KIMMTRAK), IDEAYA Biosciences (darovasertib), and Replimune Group (RP2) in the context of uveal melanoma treatment.
• It also lists companies developing and marketing devices for local regional procedures, including Boston Scientific Corporation, Medtronic plc, Merit Medical Systems, Inc., Varian Medical Systems, Inc., Sirtex Medical Limited, and AngioDynamics, Inc.

Legal Proceedings

• The company reached a final settlement with medac GmbH regarding a dispute over a milestone payment, with the company agreeing to pay either royalties on sales of CHEMOSAT units or a minimum annual payment of $0.2 million.

Stakeholder Impact

• Shareholders may benefit from increased revenue and potential future profitability.
• Employees may benefit from company growth and potential job security.
• Patients may benefit from access to new and potentially effective cancer treatments.
• Healthcare providers may benefit from offering new treatment options to their patients.

Next Steps

• Continue commercialization of HEPZATO in the United States.
• Pursue clinical trials for HEPZATO and CHEMOSAT in additional indications.
• Seek regulatory approvals for HEPZATO in other jurisdictions.
• Begin a study evaluating HEPZATO in combination with SOC for liver-dominant metastatic breast cancer in 2025.
• Enroll patients in the Phase 2 trial evaluating HEPZATO in combination with SOC for mCRC in the second half of 2025.

Key Dates